Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method and compositions for prevention or treatment of cancer

A cancer, thiomolybdate compound technology, applied in the face and protein, including energy, prevention and treatment of vascular diseases, therapeutic kits, prevention or delay of cancer onset, can solve problems such as side effects

Inactive Publication Date: 2009-10-14
RGT UNIV OF MICHIGAN
View PDF36 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Significant side effects have also been reported with penicillamine therapy, including nausea and abdominal discomfort, as well as more serious side effects such as leukopenia and thrombocytopenia, which can lead to aplastic anemia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method and compositions for prevention or treatment of cancer
  • Method and compositions for prevention or treatment of cancer
  • Method and compositions for prevention or treatment of cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0223] Cytotoxic effects of TM

[0224] The interior of normal cells and tumor cells in culture is nourished by the medium through the transport and utilization of molecules. This step is not dependent on the growth of blood vessels, so TM should have no effect on cell growth rate and cell viability over a wide concentration range, unless TM reaches levels that are toxic to most cells exposed. One mechanism of toxicity is depletion of free copper levels below that required for essential cellular functions. For TM concentrations above this toxic level, neither normal nor tumor cells will be able to survive due to the cytotoxicity of TM.

[0225] This was confirmed in cytotoxicity experiments in MML cells (prostate cancer) and breast cancer cells. After plating the same number of cells in media containing various concentrations of TM (ranging from 0.001 [mu]M to 1 mM), no toxicity was observed over the concentration range used in vivo. When the concentration of TM increased...

Embodiment 2

[0227] Use of TM in preclinical anticancer research in mice

[0228] The inventors theorize that a state of copper deficiency to a greater extent than previously achieved is necessary to significantly inhibit angiogenesis and arrest tumor growth. This means that, in addition to a reduction in tumor mass, prolonged survival or tumor regression will be observed. The studies described below using an anti-copper approach to inhibit tumor growth in rodents do not fully reflect the guidelines derived from human and animal studies of trace elements (in general) and copper (in particular) (Dick and Bull , 1945; Miller and Engel, 1960; Macilese Ammerman et al., 1969; Mills et al., 1958; Cox et al., 1960; Dick et al., 1975; Mason, 1990; McQuaid and Mason, 1991; Mills et al., 1981a; Mills et al., 1981b; Bremner et al., 1982; Gooneratne et al., 1981a,b; Jacob et al., 1981).

[0229]In contrast, the present invention uses TM, the most effective anti-copper agent known. In the developm...

Embodiment 3

[0249] Phase I / II Clinical Trial of TM as Anticancer Therapy

[0250] A. Introduction

[0251] Patients with metastatic solid tumors often have very limited treatment options due to the cumulative toxicity and drug resistance of cell-number-reducing chemotherapy. Following the preclinical work detailed above showing the efficacy of an anti-copper approach in a mouse tumor model, a Phase I clinical trial was conducted in 18 patients with metastatic cancer at three oral tetrathiomolybdate dose levels (TM: 90, 105, and 120 mg / day), administered 6 times with and between meals. Ceruloplasmin (Cp) in serum served as a surrogate marker for systemic copper levels. Since anemia is the first clinical indication of copper deficiency, the aim of the study was to reduce Cp to 20% of baseline without reducing hematocrit by more than 80% of baseline. Cp is a reliable and sensitive measure of copper status, and TM is nontoxic when Cp drops to 15-20% of baseline. Dose level III (120 mg / d...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided are agents that can bind to copper, and form a tripartite complex with protein, and the use of these agents in the prevention and treatment of diseases with a vascular component, such as solid tumors. Compositions and methods for combination therapy of these diseases, including cancer, as well as therapeutic kits, are also provided.

Description

Background of the invention [0001] This application claims priority to provisional application serial numbers 60 / 099,103, filed September 4, 1998, and provisional application serial numbers 60 / 101,759, filed September 25, 1998, the entire contents of both provisional applications being incorporated herein as refer to. The government has rights in this invention pursuant to Grant No. FD-U-000505 from the Food and Drug Administration and Grant No. R03-CA77122-01 from the National Institutes of Health. [0002] I. Field of Invention [0003] The present invention generally relates to the field of disease prevention and treatment. The invention more particularly includes agents capable of binding copper and in some respects forming a three-component complex with proteins, and the use of these agents in the prevention and treatment of vascular diseases such as cancer. Compositions and methods for combination therapy of these diseases, as well as therapeutic kits, are also provid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K47/48A61K33/24A61P35/00A61P29/00A61K45/00A61K31/28A61K31/7135A61K33/243A61K33/30A61K33/34A61P9/00
CPCA61K31/28A61K33/34A61K33/24A61P29/00A61P35/00A61P9/00A61K33/243A61K2300/00A61K47/50
Inventor G·J·布莱沃S·D·莫拉沃D·科库瓦尼斯
Owner RGT UNIV OF MICHIGAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com